Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03068455 · ClinicalTrials.gov registry record · Phase 3
An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,844
- Enrollment target
NCT03068455 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,844 participants.
The verdict
NCT03068455, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,844 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether an investigational immunotherapy Nivolumab, when combined with Ipilimumab, is more effective than Nivolumab by itself, in delaying the return of cancer in patients who have had a complete surgical removal of stage IIIb/c/d or stage IV Melanoma
Interventions
- BIOLOGICAL nivolumab
- BIOLOGICAL ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,844 participants |
| Start Date | 2017-04-11 |
| Est. Completion | 2021-02-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03068455
The ClinicalTrials.gov registry entry for NCT03068455 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,844 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which nivolumab is the first listed.
NCT03068455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03068455 about?
NCT03068455 is a clinical study titled "An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma". The purpose of this study is to determine whether an investigational immunotherapy Nivolumab, when combined with Ipilimumab, is more effective than Nivolumab by itself, in delaying the return of cancer in patients who have had a complete surgical removal of stage IIIb/c/d or stage IV Melanoma
What is the current status of trial NCT03068455?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,844 participants. The study started on 2017-04-11. Estimated completion is 2021-02-02.
What interventions are being tested in trial NCT03068455?
The interventions under investigation include: nivolumab (BIOLOGICAL), ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03068455?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.